Lv11
90 积分 2023-03-01 加入
Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial
10小时前
待确认
llogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
11小时前
已完结
CAR-T cell manufacturing: Major process parameters and next-generation strategies
9个月前
已完结
Chapter 22 - Decisions in the Development Lifecycle of Cell and Gene Therapies
1年前
已关闭
The Comparability Tales: A Phase Appropriate Roadmap for CGT Drug Product Development
1年前
已关闭
Better by design: What to expect from novel CAR-engineered cell therapies?
1年前
已完结
Optimizing the manufacturing and antitumour response of CAR T therapy
1年前
已完结
Process analytical technologies in cell therapy manufacturing: state‐of‐the‐art and future directions
1年前
已完结
Key Points from the FDA's Guidance for CAR T-Cell Products
1年前
已完结
Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: from in-silico to in-vitro
1年前
已完结
皖公网安备34019202002308
